

## RSV Vaccine Update Huron Perth November 18, 2024

### Key Messages:

- There are two RSV protection programs from the province:
  - **Infant and high-risk children RSV prevention program**
    - Infants born in 2024 and other select high-risk groups are eligible.
    - Pregnant adults are also eligible
  - **High-risk older adult RSV vaccine program**
    - for those age 60+ in Long Term Care Homes / Retirement Homes, ALC patients in hospital and select high risk groups (indigenous / underhoused / transplant / dialysis).
- Respiratory syncytial virus (RSV) protection supply is still limited at the moment. Local public health units are working closely with the Ministry of Health and the product vendor to increase supply as quickly as possible.
- **Please review the information below to prioritize how to use the RSV products your office receives.**

## What are the different RSV products (monoclonal antibodies and vaccines) and who can receive them?

### Infant RSV protection program

#### Beyfortus (monoclonal antibody) Eligibility

- Born in 2024 prior to the RSV season
- Born during the 2024/25 RSV season
- Children up to 24 months of age who remain vulnerable from severe RSV disease through their second RSV season, as they meet the Medical Criteria for Increased Risk as listed below

- Beyfortus should still be administered to the following infants whose gestational parent received Abrysvo:
  - Infants who are born less than 2 weeks after administration of Abrysvo.
  - Infants who meet the Medical Criteria for Increased Risk from severe RSV disease:
    - Chronic lung disease (CLD), including bronchopulmonary dysplasia, requiring ongoing assisted ventilation, oxygen therapy or chronic medical therapy in the six months prior to the start of RSV season
    - Hemodynamically significant congenital heart disease (CHD) requiring corrective surgery or are on cardiac medication for congestive heart failure or diagnosed with moderate to severe pulmonary hypertension
    - Severe immunodeficiency
    - Down syndrome/Trisomy 21
    - Cystic fibrosis with respiratory involvement and/or growth delay
    - Neuromuscular disease impairing clearing of respiratory secretions
    - Severe congenital airway anomalies impairing the clearing of respiratory secretions

#### Current products available

- **50mg Beyfortus**
  - a. **Infants currently under 11 pounds (5 kg)** - Beyfortus (Nirsevimab) is available for all babies born in 2024, and 2025 (during RSV season – most likely till April 2025).
    - i. Infants < 5kg are to receive one dose of **50 mg** Beyfortus in 0.5 mL (100 mg/mL)
    - ii. Since early November, hospitals have had 50 mg doses to provide to any newborns prior to discharge.
- **100mg Beyfortus**
  - b. **Infants currently equal or over 11 pounds (≥ 5kg)** - Beyfortus (Nirsevimab) is available for all babies born in 2024, and 2025 (during RSV season).
    - i. Infants ≥ 5kg are to receive one dose of **100 mg** Beyfortus in 1 mL (100 mg/mL)

ii. Since late October, hospitals have had 100 mg doses to provide any newborns  $\geq$  5kg or eligible pediatric patients prior to discharge.

- **200mg Beyfortus HR**

iii. High Risk infants entering their second RSV season are eligible for a dose of 200mg (2 x 100 mg injections). See above for high-risk infant criteria.

Please see additional information on dosing below in the Beyfortus Dosing Appendix.

### Abrysvo (bivalent, subunit vaccine) Eligibility

- For those in pregnancy (32-36 weeks gestation)
  - Available for pregnant individuals to protect newborns from RSV from birth until they are six months old.
  - Multi-year protection, do not need to repeat if vaccinated last year
  - The infant product Beyfortus is the recommended approach for protection of infants per the National Advisory Committee on Immunization (NACI), with the vaccine in pregnancy being available on a case-by-case basis.

### High-risk older adult RSV vaccine program

#### Abrysvo (bivalent, subunit vaccine) Eligibility

- **Abrysvo**, for age 60+ in Long Term Care Homes / Retirement Homes, ALC patients in hospital and select high risk groups (indigenous / underhoused / transplant / dialysis).
- Multi-year protection, do not need to repeat if vaccinated last year

#### Arexvy (recombinant, adjuvanted vaccine) Eligibility

- For age 60+ in Long Term Care Homes / Retirement Homes, ALC patients in hospital and select high risk groups (indigenous /underhoused/transplant/dialysis).
- Multi-year protection, do not need to repeat if vaccinated last year

## I'm a primary care provider. What types of RSV products (monoclonal antibodies and vaccines) can I order?

- All 3 products (**Abrysvo**, **Arexvy** or **Beyfortus**) are available for primary care providers to order ([RSV order form for hospital & healthcare providers](#)).
- We have had a limited quantity of **Beyfortus** from the province. As additional **Beyfortus** comes into the province and to health units, communication will be sent out and orders will be filled.
  - As orders are filled, they will be available for pickup or delivery around the normal routine ordering schedules. If offices would like products earlier than their scheduled delivery date, please contact the Inventory Program Administrative Assistants (Tanya or Cris) to discuss pick-up options.
- The majority of **Abrysvo** and **Arexvy** was delivered and administered at retirement and long-term care homes for eligible residents.

## What information can I share with my patients about RSV products?

Please share the following:

[For Parents and Expectant Parents: Protecting Your Child from RSV](#) | Provincial Council for Maternal and Child Health

[Beyfortus Parent Brochure](#) | Sanofi

[Abrysvo Factsheet](#) | Ontario Ministry of Health

[Older Adult High-Risk Respiratory Syncytial Virus \(RSV\) Vaccine Program Fact Sheet](#) | Ontario Ministry of Health

## How are hospitals receiving RSV vaccine?

- Initially the hospitals received a direct shipment of Beyfortus (50 mg and 100mg) from Sanofi. If additional doses are required, hospitals are aware to place an order by completing the [RSV order form for hospital & healthcare providers](#).

## Where can I go for future updates?

- Please visit [www.hpph.ca/RSV](http://www.hpph.ca/RSV) for more updates. You will also continue to receive direct updates and phone calls about the number of doses coming in your orders.
- Contact the HPPH Immunization Team at 1-888-221-2133 Ext. 3558

## Resources:

[Infant and High-risk Children Respiratory Syncytial Virus \(RSV\) Prevention Program Guidance for Health Care Providers – Beyfortus® \(Nirsevimab\)](#) | Ontario Ministry of Health

[Older Adult High-Risk Respiratory Syncytial Virus \(RSV\) Vaccine Program Fact Sheet - Health Care Providers](#) | Ontario Ministry of Health

[Respiratory Syncytial Virus Prevention Programs](#) | Ontario Ministry of Health

# Beyfortus Dosing Appendix



RSV – Infant (under 12 months of age)

- 50 mg if baby weighs less than 5 kg (**Purple** plunger rod = **P**etite baby)

OR



- 100 mg if baby weighs 5 kgs or more (**B**lue plunger rod = **B**ig baby)

RSV – High Risk (12 to 24 months of age)

- 200mg (2 x 100 mg injections) if second season and at continued high-risk from RSV infection.

## Beyfortus Dosing:

50 mg (for infants < 5 kg), or 100 mg (for infants ≥ 5 kg)

Beyfortus® 50 mg (50mg/0.5 mL) prefilled syringe with a purple plunger rod.	Beyfortus® 100 mg (100 mg/mL) prefilled syringe with a light blue plunger rod
	

\*Prefilled syringe. Need to add a tip.

**Table 1: Beyfortus® Administration Guidelines for Infants and Children**

Category	Weight	Dose	Timing
Infants born during the current RSV season <sup>∞</sup>	< 5 kg	50 mg in 0.5 mL (100 mg/mL)	Administered from birth
	≥ 5 kg	100 mg in 1 mL (100 mg/mL)	Administered from birth
Infants born in 2024 before the current RSV season starts (up to 12 months of age)*	< 5 kg	50 mg in 0.5 mL (100 mg/mL)	Shortly before the start of the RSV season <sup>∞</sup>
	≥ 5 kg	100 mg in 1 mL (100 mg/mL)	Shortly before the start of the RSV season <sup>∞</sup>
Children over 12 months and up to 24 months of age and at continued high-risk from RSV infection	N/A	200 mg (two 1 mL injections of 100 mg/mL) <sup>†</sup>	Shortly before the start of their second RSV season <sup>∞</sup>
<p>∞ Due to the seasonality of the RSV virus, Beyfortus should be administered shortly before and during the active RSV season. The RSV season is generally from November to April, peaking in December, with variations in various regions in Ontario and between years.</p>			
<p>*NACI recommends Beyfortus especially for infants less than 8 months of age due to risk of severe outcomes in younger infants.</p>			
<p>†If a child weighs less than 10 kg entering their second RSV season, consideration can be given to administering a single dose of 100 mg at the clinical discretion of the provider.</p>			

Provincial RSV Website:

<https://www.ontario.ca/page/respiratory-syncytial-virus#:~:text=2023%20RSV%20season-,Through%20the%20Respiratory%20Syncytial%20Virus%20Prophylaxis%20for%20High%2DRisk%20Infants,2%20years%20of%20age%20at>